STAMFORD, Conn., Aug. 28, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced ...
SpringWorks Therapeutics (SWTX) has announced that the U.S. Food and Drug Administration has approved Gomekli, a small molecule MEK inhibitor, for the treatment of adult and pediatric patients 2 years ...
Presented positive topline data from the pivotal Phase 2b ReNeu trial evaluating mirdametinib, an investigational oral MEK inhibitor, in pediatric and adult patients with neurofibromatosis type ...
SpringWorks Therapeutics, Inc. SWTX expanded its existing clinical collaboration agreement with GSK GSK. The partnership is evaluating the combination of SpringWorks’ investigational oral gamma ...
Desmoid tumors, though benign, are locally aggressive with tendril-like growths causing pain, limited range of motion and even impaired mobility. (SpringWorks) SpringWorks Therapeutics is launching a ...
NEW YORK--(BUSINESS WIRE)--SpringWorks Therapeutics, a mission-driven medicines company dedicated to developing innovative potential new treatments for underserved patient communities, announced its ...
FDA approved SpringWorks' mirdametinib for NF1 patients with symptomatic plexiform neurofibromas, granting a priority review voucher. In the Phase 2b trial, Gomekli showed a 41% ORR in adults and 52% ...
Nov 28 (Reuters) - SpringWorks Therapeutics' (SWTX.O), opens new tab drug for treating adult patients with a type of rare non-cancerous soft-tissue tumor will be sold in the U.S. at a list price of ...
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. & SAN MATEO, Calif. & STAMFORD, Conn.--(BUSINESS WIRE)--MapKure, LLC, BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE ...
Investing.com -- Shares of SpringWorks Therapeutics Inc (NASDAQ:SWTX) surged higher Thursday afternoon on reports that a potential takeover of the company by Germany’s Merck KGaA (ETR:MRCG) is getting ...
– Approval based on positive data from Phase 2b ReNeu trial, which showed GOMEKLI treatment resulted in robust ORR, deep and durable reductions in tumor volume, and ...
“SpringWorks is committed to developing genomically-targeted therapies for patients with cancer and our MAPK directed portfolio is a cornerstone of our efforts. In particular, we are encouraged by the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results